Frazier Life Sciences Management L.P. Grows Stock Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Frazier Life Sciences Management L.P. lifted its position in shares of HilleVax, Inc. (NASDAQ:HLVX) by 8.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,617,062 shares of the company’s stock after purchasing an additional 835,590 shares during the period. HilleVax accounts for about 7.2% of Frazier Life Sciences Management L.P.’s holdings, making the stock its 4th biggest position. Frazier Life Sciences Management L.P. owned approximately 0.21% of HilleVax worth $153,523,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Affinity Asset Advisors LLC bought a new position in shares of HilleVax during the second quarter valued at about $3,844,000. Fred Alger Management LLC raised its position in HilleVax by 9.7% in the second quarter. Fred Alger Management LLC now owns 136,166 shares of the company’s stock worth $1,969,000 after acquiring an additional 12,044 shares during the period. Ensign Peak Advisors Inc raised its position in HilleVax by 164.8% in the second quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company’s stock worth $4,508,000 after acquiring an additional 194,038 shares during the period. Renaissance Technologies LLC raised its position in HilleVax by 119.8% in the second quarter. Renaissance Technologies LLC now owns 56,700 shares of the company’s stock worth $820,000 after acquiring an additional 30,900 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in HilleVax by 31.7% in the second quarter. Dimensional Fund Advisors LP now owns 152,602 shares of the company’s stock worth $2,204,000 after acquiring an additional 36,690 shares during the period. 86.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on HLVX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $5.00 price objective (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Stifel Nicolaus lowered shares of HilleVax from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $34.00 to $3.00 in a research report on Tuesday, July 9th. Leerink Partnrs lowered shares of HilleVax from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of HilleVax in a research report on Monday, August 12th. Finally, Leerink Partners lowered shares of HilleVax from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $28.00 to $2.00 in a research report on Tuesday, July 9th. Six investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.20.

HilleVax Stock Down 1.7 %

NASDAQ HLVX opened at $1.76 on Friday. The company’s 50 day moving average is $1.80 and its 200-day moving average is $9.01. HilleVax, Inc. has a 12-month low of $1.55 and a 12-month high of $20.22. The firm has a market cap of $87.51 million, a P/E ratio of -0.53 and a beta of 0.81.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). Equities analysts expect that HilleVax, Inc. will post -2.47 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.